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 Despite the widespread use of Highly Active Anti-retroviral Therapy (HAART) to 
combat Human Immunodeficiency Virus (HIV), the causative agent of acquired 
immunodeficiency syndrome (AIDS), HIV-Associated Neurocognitive Disorders 
(HANDs) still remain a dire issue.  HIV can enter the brain through infected monocytes 
and infect microglia, the resident macrophages within that compartment.  Due to its pro-
   
 xii 
inflammatory properties, HIV regulatory protein Tat (Transactivating protein) may play a 
role in the progression of neurocognitive disorders. 
  The aim of this project was to determine whether the select cannabinoids THC and 
CP55,940  could ablate the inflammatory response on BV-2 mouse microglia cells caused 
by Tat.  Within the constraints of the experiment, no major effects of cannabinoid 
treatment were observed at the level of the proteome as tested by two-dimensional gel 
electrophoresis .  In contrast, these cannabinoids ablated the inflammatory response caused 
by the HIV protein Tat at the level of the secretome and at the level of gene expression. 
These collective observations suggest that select cannabinoids have the potential to down-
regulate the elicitation of  proinflammatory gene products that are engendered by the HIV 
protein Tat. Furthermore, the results suggest a potential for cannabinoid agonists at 
cannabinoid receptors to serve as adjunct ablative agents in the treatment of HIV-
associated neuropathological processes. 
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Introduction 
 
 
Human Immunodeficiency Virus 
 The Human Immunodeficiency Virus (HIV) is an enveloped lentivirus, a member 
of the retrovirus family, that is the causative agent of acquired immunodeficiency 
syndrome (AIDS).  According to the Centers for Disease Control and Prevention (CDC, 
2010), approximately 1,148,200 people aged 13 and older are living with HIV infection in 
the United States of America.  Of the infected population, approximately 1 in 5, or 20%, 
are unaware that they are infected (CDC).  HIV has the ability to infect many cell types, 
principally CD4+ T cells and macrophages, with macrophages typically being the earlier 
cellular target (Carter and Ehrlich, 2008).  Eventually,  HIV infection of  immune cells 
leads to the loss of cell-mediated immunity, causing the body to become more susceptible 
to opportunistic infections.  In addition, HIV is able to cross the blood-brain barrier (BBB) 
via infected macrophages and enter the central nervous system (CNS) early in HIV 
infection. (McArthur, 2005). 
 
HIV-Associated Encephalitis 
  Due to the physical and cellular barrier provided by the BBB, the majority of 
pathogens cannot penetrate and infect the brain (Reviewed by Chiara, 2012). Among the 
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few viruses that can enter the brain and cause encephalitis, such as  herpes simplex virus 
type 1(HSV-1), cytomegalovirus (CMV), Varicella zoster, and Epstein-Barr virus, HIV-1 
is the leading cause of dementia (Almeida, 2005, Wang, 2006).  The most widely accepted 
theory of how lentiviruses such as HIV enter into the CNS is through the “Trojan Horse” 
mechanism (Peluso, 1985).  In this mechanism, the virus is trafficked into the brain by 
infected monocytes that can cross the BBB and then release the virus into the CNS.  It has 
been reported that HIV can enter the brain as early as 15 days after systemic infection 
(Davis, 1992).  While neurocognitive effects are rare in the asymptomatic phase of HIV 
infection, they can progress in the later stages of the disease (McArthur et al, 1989).  
According to a review by Ghafouri et al (2006), although there is a wide range of 
symptoms, neurological impairments affect approximately 60% of HIV-infected patients.  
The progressive cognitive disorders associated with HIV were originally described by 
Navia et al. (1986) under the name “AIDS dementia complex” (ADC).  Since then, a 
collection of names, including HIV-associated dementia (HAD), HIV-Associated 
Neurocognitive Disorders (HANDs), and HIV encephalitis (HIVE) have been used to 
describe various cognitive disorders associated with HIV.   
As discussed by Ghafouri et al, (2006) highly active anti-retroviral therapy 
(HAART) has substantially reduced, though not eliminated, the percentage of the AIDS 
population that suffers from HAD.  Since HAART began in 1995, however, a more mild 
form of CNS dysfunction, called minor cognitive motor disorder (MCMD) has become 
increasingly common in HIV patients.  HAART, however, is not designed to target the 
inflammatory cascade underlying HAD and MCMD, and in addition, protease inhibitors 
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cannot cross the BBB. Furthermore, HIV-1 RNA levels in the CNS do not always correlate 
with the degree of neurologic impairment in the course of HIV-associated dementia (Bossi 
et al., 1998).  Thus, with the increase of use of HAART and as HIV-positive patients begin 
to live longer with the disease, it is anticipated that the range and prevalence of HIV-
associated neurological diseases will increase, so treatment of HIV-1 associated dementia 
remains a dire issue.  
 
Transactivating Protein (Tat) 
It has been suggested that soluble mediators, such as the HIV pro-inflammatory 
protein Tat (transactivating protein),  play a role in progression of the disease and could be 
responsible for encephalitis in the brain in the absence of abundant infection of the HIV 
virus itself (D’Aversa, 2004).  First demonstrated by Dayton et al. (1986), HIV Tat is a 
viral regulatory protein that is necessary for both viral transcription and replication.  As 
reviewed by Pugliesi et al. (2006), Tat has several subtypes that consist of between 72 and 
101 amino acids depending on specific mRNA splicing.  Tat protein is encoded by 2 
exons.  Exon 1 encodes amino acids 1-72, while exon 2 can encode either amino acids 73-
86 or amino acids 73-101.  Tat acts by accumulating in the nucleus of infected cells and 
enhancing viral transcription by binding to specific sequences of the Transactivation 
Response Element (TAR).  Through this interaction, Tat recruits a myriad of 
transcriptional complexes, including histone acetyltransferases (HATs) and factor 
acetyltransferases (FATs), which promote elongation of viral RNA transcription (Brigati et 
al 2006). Tat also can activate transcription factor Nuclear Factor-kappaB (NF-kB) 
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(DeMarchi, 1996). Tat also activates glial cells to produce cytokines and chemokines such 
as Tumor Necrosis Factor (TNF)-α (Chen, 1997). 
While Tat can remain intracellular, it also can act as a pleiotropic exogenous factor, 
and can regulate cellular activities related to survival, growth, inflammation, and 
angiogenesis (Brigati et al., 2006, Chang et al. 1995).  Tat has been detected both within 
the CNS (Hudson et al., 2000) and in the serum of patients infected with HIV (Westendorp 
et al., 1995).  Tat released from infected macrophages and microglia can enter neighboring 
neurons where it has pro-apoptotic potential (Ramirez, 2001).  Extracellular Tat also 
activates neighboring cells, triggering even more production of chemokines and cytokines 
(D’Alversa, 2004).  HIV-1 Tat protein also upregulates inflammatory mediators and 
induces monocyte invasion into the brain (Pu, 2003).   
 
Microglia 
There are five main cells types in the brain that are susceptible to the action of  
HIV infection: astrocytes, oligodendrocytes, neurons, perivascular macrophages, and 
microglia (Gonzalex-Scarano & Martin-Garcia, 2005). Microglia cells are one of three 
main glial cell types in the CNS.  It is generally believed that during embryonic 
development, monocytes in the bloodstream are able to enter the brain and can then 
separate into resident microglial cells.  Once activated, microglial cells act as immune 
stimulators and can lead to neurodegeneration, and in turn a variety of neurological 
disorders caused by neuroinflammation.  Microglia can act as viral reservoirs that secrete 
inflammatory mediators and toxins that can affect the surrounding environment in the 
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central nervous system. Macrophages and microglia play a crucial role in HANDs and 
HIVE because they constitute the majority of cells infected with HIV-1 within the CNS 
(Lipton and Gendelman, 1995).  Once a patient is infected with HIV-1, circulating 
monocytes in the body can migrate to the brain, where other cell types, including 
microglia, can be infected. 
Because primary microglia cultures have many limitations for in vitro use, such as 
limited proliferation capacity and difficulty of obtaining pure cultures, microglial cell lines 
have become widely popular as experimental models, including both human and murine 
models.  The murine BV-2 microglia cell line was produced through immortalization by a 
v-raf/v-myc oncogene carrying J2 retrovirus, (Blasi et al., 1990) and often is used as a 
substitute for primary microglia (PM) for in vitro experimentation.  When activated by 
bacterial lipopolysaccharide (LPS), BV-2 cells elicit an overall response pattern of 
inflammatory genes that parallels that of primary microglial cells (PMs)  (Henn, 2009).  In 
addition, BV-2 cells behave similarly to PMs in assays examining Mitogen-Activated 
Protein (MAP) kinase signaling (Lund et al. 2005). 
 
Cannabinoids and Cannabinoid Receptors 
Originally isolated from the marijuana plant Cannabis sativa, exogenous 
cannabinoids represent a group of pharmacological compounds that have a wide array 
physiological and psychotropic effects on humans.  Δ9-tetrahydrocannabinol (THC), the 
major active ingredient of cannabis, was first isolated from hashish in 1964 (Gaoni and 
Mechoulam, 1964).  In addition to its drug abuse potential, THC is responsible for a 
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multiplicity of effects in the CNS, including alterations in mood, perception, cognition, and 
memory (Dewey, 1986).  As reviewed by Cabral and Pettit (1998), THC also has 
immunosuppressive properties that can decrease host defense in both guinea pigs and 
murine models to a variety of bacterial and viral infections.  
 Presently, two cannabinoid receptors (CB1 and CB2) have been discovered.  CB1 
was first isolated and cloned from rat cDNA (Matsuda, 1990), and CB2 was cloned shortly 
after from a human promyelocytic cDNA library (Munro, 1993).  While both receptors are 
coupled to G-Proteins, CB1 is very abundant in the CNS, reaching high densities in the 
cerebellum, basal ganglia, hippocampus, and cortex (Pertwee, 1997).  On the other hand, 
CB2 is found primarily in immune cells (Munro, 1993) and appears to play a major role in 
immune modulation (reviewed by Cabral and Dove Pettit, 1998) by regulating immune cell 
migration and cytokine release (reviewed by Cabral and Staab, 2005).  Both the CB1 and 
CB2 receptors inhibit adenylyl cyclase and activate MAP kinase signaling (Howlett, 2005).  
Due to its location in the brain, activation of CB1 can affect memory and cognition 
processes and alter control of motor function (Pertwee, 2004).  Microglia, the main cells in 
the CNS targeted by HIV, express the CB2 during CNS inflammation in models associated 
with HIV infection (Benito et al, 2005).   
There are several receptor agonists that bind to CB1 and CB2, including THC and 
CP55940.  The discovery that exogenous cannabinoids could alter function through the 
cannabinoid receptors implied the existence of an endogenous cannabinoid system (the 
endocannabinoids).  As reviewed by Pertwee (2006), the distribution pattern of CB1 within 
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the CNS is consistent with those areas that are associated with the major psychotropic 
effects of THC. 
 
Rationale and Objectives 
 Because neuroinflammation and the associated neurocognitive disorders remain a 
major concern with HIV-positive individuals and studies have shown that Tat has  pro-
inflammatory properties, the goal of this investigation was to assess the potential of select 
cannabinoids to ablate the microglial inflammatory response to HIV protein Tat.  
Microglial cells, specifically BV-2 mouse cells, were the focus of study since they 
represent the most HIV replication-competent cell population in the brain and the major 
reservoir of HIV in the CNS. The cannabinoids used in the study were THC  (a partial 
agonist at cannabinoid receptors) and CP55,940 (a full agonist at cannabinoid receptors), 
which have both been previously known for their anti-inflammatory properties. THC was 
included in the study specifically because of its drug abuse implications in smoked 
marijuana and to assess whether, at least in vitro, it exacerbated the microglial immune 
response to Tat.  
 In order to address this goal, first, in vitro models of mouse microglial cells were 
established and proven to be viable following treatment with Tat, THC, and CP55940.  
Second, different protein profiles between different treatment groups were assessed using a 
high-resolution two-dimensional gel proteomics approach.  Finally, a limited assessment of 
the secretome was undertaken through analysis of levels of cytokines and chemokines and 
their cognate mRNA species at  the gene expression level. The collective results indicated 
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that THC and CP55940 ablated the inflammatory response of BV-2 mouse microglia-like 
cells exposed to exogenously-introduced Tat primarily by downregulating the levels of 
pro-inflammatory cytokines and chemokines. 
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Materials and Methods 
 
 
Cells 
The murine BV-2 cell line, produced through immortalization by a v-raf/v-myc 
oncogene carrying J2 retrovirus (Blasi et al., 1990), was obtained from Dr. Michael 
McKinley (Mayo Clinic, Jacksonville, FL). Cell cultures were maintained at 37°C with 5% 
CO2 in ventilated T-175 flasks in complete Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Mediatech, Herndon, VA) supplemented with 1% each of L-glutamine, non-
essential amino acids, and MEM vitamins, 0.01M HEPES buffer, penicillin (100 
IU/ml)/streptomycin, (100 µg/ml)/amphotericin B (0.25 µg/ml) and 10% heat-inactivated 
fetal bovine serum (HI-FBS). For experiments, because Tat attached to plastic, special 
low-retention microfuge tubes (Thermo Fisher Scientific, Waltham, MA) and low-binding 
pipette tips (VWR, West Chester, PA) were used. Confluent BV-2 cells were detached 
from culture flasks using a cell scraper (BC Falcon, Franklin Lakes, NJ) and were seeded 
at a density of 1 x 106 cells. 
 
Drugs 
 The partial CB1R/CB2R agonist Delta-9-tetrahydrocannabinol,THC (CB1R Ki = 
40.7 nM; CB2R Ki = 36.4 nM), and the full CB1R/CB2R agonist CP55940 (CB1R and 
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CB2R Ki = 1.37 nM) were obtained from the Department of Pharmacology and 
Toxicology (Virginia Commonwealth University, Richmond, VA).  HIV-1 Tat1-101 was 
purchased from Immunodiagnostics (Woburn, MA).  Stock solutions of Tat (10uM) were 
prepared in Sodium Citrate.  Vehicle controls for Tat consisted of the same volume of 
sodium citrate that was used to dilute Tat in DMEM.  Stock solutions of cannabinoids (10-
2M) were prepared in 100% ethanol and stored at -20°C.  Stock solutions of cannabinoids 
were diluted in DMEM immediately before use to yield a final concentration of 10-6 M and 
ethanol concentration of 0.01%.    Controls for cannabinoids consisted of equal volumes of 
ethanol. 
 
Treatment of BV-2 Cells 
 BV-2 cells were seeded at a concentration of 106 cells/ well in serum-free media.  
They were then treated for 8h with sodium citrate buffer + vehicle (veh, 0.01% ethanol), 
Trans-Activator of Transcription (Tat) (50 nM) +  veh, Tat (50 nM) + THC (10-6 M), or 
Tat (50 nM) + CP55940 (10-6 M) at 37ºC. After incubation time, the supernatant was 
collected and employed to assess cytokine/chemokine secretion through antibody 
membrane arrays (Bio Rad, Richmond, CA). Additionally, RNA was isolated and whole 
cell lysates were prepared for two dimensional electrophoresis.  
 
Whole Cell Lysate and Protein Concentration 
 For analysis by 2-D gel electrophoresis, after treatment for 8h, cells were scraped 
from the bottom of the plate with PBS and were centrifuged (1000 rpm, 3 min).  The 
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supernatant was collected and the cells were washed with PBS and centrifuged again (1000 
rpm, 3 min).  Thirty µl lysis buffer (7M urea, 2M thiourea, 4% CHAPS detergent, 30mM 
Tris buffer, 5nM magnesium acetate at pH 8.5) were added to each sample.  Lysates were 
placed on ice for 30 min, sonicated (5X), and placed on ice for an additional 10 min.  
Samples were then centrifuged (12,000 xg, 10 min, 4ºC) and kept at -80ºC.  Protein 
concentration was determined  using the RC/DC protein kit (Bio Rad) according to the 
Lowry method (Lowry, 1951) by comparing samples to standard volumes of bovine 
albumin serum (BSA). 
 
MTT Assay 
 The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
assay was performed in order to ensure BV-2 cell viability with treatment.  After 8 h 
treatment as described above, cell viability was measured by the reduction of MTT by 
viable mitochondria in a colorimetric assay described by Mosmann. (Mosmann, 1983).  
The absorbance was read with a SpectraMax 250 spectrophotometer (MDS Analytical 
Technologies) with a wavelength of 595 nm with a correction wavelength of 655 nm.  The 
level of MTT reduction was expressed graphically as a percentage of that of the negative 
control (BV-2 cells in veh). Streptomycin was used as a positive control, since it induces 
apoptosis.  
 
Two-Dimensional Gel Electrophoresis 
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  The whole cell lysate (50ug) was combined with 300ul of rehydration buffer (Bio 
Rad) to hydrate a Readystrip 17 cm IPG strip (BioRad, pH 5-8) overnight according to 
manufacturer protocol.  Mineral oil was added on top of the strip to prevent evaporation.  
IPG strips were subjected to electrofocusing for approximately 40,000 Volt-hours using 
the BioRad Protean IEF Cell unit.  Strips then were stored at -80°C until used for second 
dimension electrophoresis. Before electrophoresis, strips were equilibrated for 15 min in 
both Equilibration Buffer I and II (BioRad).  The second dimension was resolved in a 10% 
SDS-polyacrylamide gel using a BioRad power pac 1000 at a constant current constant of 
40 mA. Gels were immediately preceded to Vorum silver stain that is compatible with 
Mass Spectrometry.    
 
Vorum Silver Staining of Two-Dimensional Gels 
 Two-dimensional gels were subjected to Vorum silver staining as described by Lin 
et al (2008). Briefly, after gel electrophoresis, the gel was placed overnight in fixative 
consisting of 50% methanol, 12% acetic acid, and 0.05% formalin.  The following day, the 
gel was washed three times (20 min each) with 35% ethanol. The gel then was washed 
twice (10 min each) with distilled water and sensitized (2 min) with 100mM sodium 
thiosulfate (Fisher) and 30mM potassium ferrocyanide (Amresco Solon, OH).  The gel 
then was washed four times with water (4 min each).  The gel then was treated (20 min) 
with 0.2% silver nitrate (Amresco) and 0.076% formalin.  Following a wash (twice, 1 min 
each) with distilled water, the gel was developed (3-5 min) in a solution consisting of 6% 
sodium carbonate (VWR), 0.05% formalin, and 0.0004% sodium thiosulfate.  
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Development was terminated by immersion of the gel in a solution of 50% Methanol and 
12% acetic acid for 5 min and washing in water for 10-15 min. Gels were scanned 
immediately after the water wash.   
 
Analysis of Two-Dimensional Gels 
 Silver-stained gels were scanned using a ScanMaker 9800XL (Microtek) and 
analyzed using PDQuest version 8.0 differential analysis software (BioRad).  Each 
treatment group was performed in triplicate, and using the spot-detection software, the 
density of spots was compared between replicate gels and between different experiments.   
 
RayBio Mouse Cytokine Antibody Array 
 BV-2 cells (106 cells/ well) were treated for 8h with veh, Tat (50 nM) + veh, Tat 
(50 nM) + THC (10-6 M), or Tat (50 nM) + CP55940 (10-6 M) at 37ºC.  After treatment of 
BV-2 cells, supernatants were subjected to a mouse cytokine antibody array 3 
(RayBiotech, Inc., Norcross, GA.) according to the provided protocol in order to assess the 
levels of chemokines and cytokines in culture supernatants.  Membranes from the 4 
experimental groups were blocked in blocking buffer for 30 min at room temperature, and 
then were incubated overnight with supernatants from each of the four treatment groups at 
4°C. Membranes were washed 3 times (5 min each) with Wash Buffer I and 2 times (5 min 
each) with Wash Buffer II and incubated with biotin-conjugated antibody for 2 h. 
Following the repetition of washes, membranes then were incubated with HRP-streptavidin 
(1:1,000) for 2 h.  The membranes then were washed and developed by 
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chemiluminescence using  the kit provided (250ul Detection Buffer C and 250ul Detection 
Buffer D) and exposed to Kodak BioMax XAR Film for 5  sec.  The film was scanned on a 
Microtek ScanMaker 9800XL/TMA1600flatbed scanner (Microtek Lab Inc., Cerritos, 
CA). To determine relative concentration, the density of each spot was quantified and 
compared to standards using Quanti One software (BioRad). 
 
RNA Isolation  
 BV-2 cells (106 cells/ well) were treated for 8h with veh, Tat (50 nM) + veh, Tat 
(50 nM) + THC (10-6 M), or Tat (50 nM) + CP55940 (10-6 M) at 37ºC. Total RNA was 
isolated from cells using TRIzol reagent (InvitrogenTM Life Technologies, Carlsbad, CA) 
according to the manufacturer's instructions.  A chloroform-isopropanol extraction was 
performed, and the RNA was resuspended in 30µl sterile water.  RNA cleanup was 
performed using a RNeasy Mini (Qiagen) kit according to the manufacturer's instructions.  
The 260 nm/280 nm ratio of RNA was taken to ensure integrity and the RNA was run on a 
1.5% agarose gel and . 
 
cDNA Synthesis and RT-PCR 
 Real-time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) was used 
to assess the presence of mRNA of select cytokines and chemokines under varying 
experimental conditions.  Messenger RNA (1µg) was used to generate cDNA. The cDNA 
synthesis was performed with a RT2 First Strand kit (Qiagen) according to manufacturer's 
instructions.  RT-PCR was performed using iQ SYBR Green SuperMix (Bio Rad). Plates 
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were placed in the SmartCycler (Cepheid, Sunnyvale, CA), and PCR was performed using 
the following program 95°C, 15 min; 40 cycles of (95°C, 30 sec; 55°C, 30 sec; and 72°C, 
30 sec.  Resulting PCR products were determined using the threshold cycle (Ct) values for 
each of the genes on the array.   The result was analyzed by the Qiagen website program 
and plotted as heat maps or bar graphs.  Fold changes in gene expression were calculated 
using the ΔΔCt method.  Built-in RNA quality controls were also utilized to provide the 
relative levels of genomic DNA contamination and inhibitors of either the reverse 
transcription or the PCR itself. By examining the Ct value consistency for the 
housekeeping genes a normalization method  was determined. 
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Results 
 
 
BV-2 Cell Viability 
Initial experiments were designed to determine the optimal concentration of 
cannabinoid to be used in BV-2 microglia-like cell cultures that did not elicit overt 
cytotoxic effects. Two approaches were employed to confirm cell viability: MTT assay and 
light microscopy. Because MTT reduction can only occur in metabolically active cells, the 
MTT assay determines mitochondrial activity, which relates to the total number of viable 
cells.  The MTT assay employs the conversion of water-soluble MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to an insoluble formazan, which is 
then solubilized.  The concentration then can be determined by measuring optical density.  
Any increase or decrease in formazan concentration represents correspondingly an increase 
or decrease in the number of viable cells.  The MTT assay (Figure 1) demonstrated that 
after 8h of treatment, cells treated with 10-5 M THC and CP55940 were not viable, (≤ 50% 
of cells in culture were viable).  Cells treated with 10-6 M of THC exhibited approximately 
70% viability and cells treated with 10-6 M CP55940 exhibited approximately 100% 
viability.  Thus, the percentage viability of BV-2 cells was always greater for CP55940 
versus THC regardless of what cannabinoid was employed in the presence of absence of 
Tat.  These results were confirmed by light microscopy examination of cells maintained  
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Figure 1. Viability of BV-2 Mouse Microgia-like Cells Treated with Varying 
Concentrations of HIV Protein Tat and Cannabinoids Measured by Hydrolysis of 
MTT by Mitochondria of Viable Cells. BV-2 cell cultures were treated (8h) with vehicle 
or cannabinoids (10-6 or 10-5M) in the presence or absence of Tat (50nM).  The graph 
represents percentage viability compared with that of cells maintained in vehicle consisting 
of sodium citrate and 0.01% ethanol in medium. 
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Figure 2. Light Microscopy of BV-2 Cells Exposed to Tat and Cannabinoids.  BV-2 
cells (106/well) were maintained in vehicle (0.01% ethanol), Tat (50nM) + vehicle, and 
cannabinoid THC or CP55940 (10-6M) + Tat for the identified time periods. The bar in 
each panel represents 100µm. 
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for 8h in 10-6M cannabinoid.  BV-2 mouse microglial cells were examined before 
treatment (Figure 2a-d), 2h post-treatment (Figure 2e-h), 4h post-treatment (Figure 2i-l), 
6h post-treatment (Figure 2m-p), and 8h post-treatment (Figure 2q-t).  Cells maintained 
viability throughout this time course of examination.  Consistent with the MTT assay data,  
treatment with 50nM Tat in the presence of cannabinoid 10-6 M did not alter cell shape or 
cell viability.  Based on these collective results, an experimental model of 8h simultaneous 
treatment with 10-6M and 50nM Tat was selected. 
 
BV-2 Intracellular Protein Profile 
 A two dimensional (2-D) gel electrophoresis approach that combines isoelectric 
focusing with SDS-PAGE was employed for assessment of the BV-2 intracellular 
proteome.  This approach was selected because it allows for the separation and 
quantification of a multiplicity of proteins on a single gel (O’Farrell, 1974).  BV-2 cells 
were treated (8h) with vehicle (sodium citrate + 0.01% ethanol), Tat (50nM + 0.01% 
ethanol), Tat + THC (50nM Tat + 10-6M THC), and Tat + CP55940 (50nM Tat + 10-6M 
CP).  Each group was run in triplicate.  The results of a representative gel from each 
treatment group are shown in Figure 3.  Each protein was identified as having a specific 
isoelectric point and molecular weight coordinate using PDQuest 8.0 software based on 
alignment of triplicate gels to create a master gel and alignment to match corresponding 
spots.  Assessment of the master gel and analysis of the density of each spot allowed for  
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Figure 3. Two-Dimension Gel Protein Profiles of Whole Cell Homogenates of BV-2 
cells treated with Tat and Cannabinoids. A representative Vorum silver stained gel from 
3 separate experiments of  BV-2 mouse microglia-like cells treated with 0.01% ethanol and 
sodium citrate (A), 50nM Tat + 0.01% ethanol (B), 50nM Tat +  10-6 M THC (C), and 
50nM Tat + 10-6 M CP55940 (D).  Samples shown were subjected to isoelectric focusing 
with 17 cm IPG Readistrips with a pH range of 5-8 and then were subjected to 10% SDS-
PAGE in the second dimension.  The horizontal axis represents protein separation by 
isoelectric focusing, while the vertical axis represents protein separation by relative 
molecular weight (kDa). 
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Figure 4. Representative Two-Dimensional Vorum-stained Gel Depicting Assessment 
of Coordinate Spot Identification Used for Establishing Scatterplot Analysis 
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Figure 5. Scatterplot Spot Comparison Between Replicate Two-Dimensional Gels.  
PDQuest version 8.0 software was employed to identify, relative spot densities from each 
gel.  Samples were analyzes in triplicate and subjected to comparison between treatment 
groups.  The blue and red lines represent 2.0 standard deviation up-regulation and 2.0 
standard deviation down-regulation, respectively. 
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the comparisons between group and the construction of scatter plots (Figure 5).  A 
representative Vorum-stained gel that has been subjected to spot analysis is shown in 
Figure 4.  Gels treated with vehicle as compared with gels treated with Tat had a total 
matched spot count of 336 with a correlation coefficient of 0.8965 (Figure 5a).  Gels 
treated with Tat and as compared with gels treated with Tat + THC shared 322 spots, with 
a correlation coefficient of 0.8985 (Figure 5b).  Gels treated with Tat as compared with 
gels treated with Tat + CP55940 shared 274 spots with a correlation coefficient of 0.9107 
(Figure 5c).  In each graph, dots lying outside of the blue and red lines represent 2-fold 
higher level or 2-fold lower level of expression, respectively.  Analysis of these gels 
indicated that there was a large degree of homology between the different treatment 
groups.  While there were several individual  proteins that showed a larger than 2-fold 
higher level or lower level with a given treatment, the majority of proteins exhibited no 
major differences in level, as least within the constraints of time, Tat, and cannabinoid 
exposure paradigm employed.   
 
Cytokine and Chemokine Protein Profiles Secreted by BV-2 cells 
 Assessment of the BV-2 extracellular chemokine/cytokine profile was undertaken 
using a membrane array system (RayBiotech).  Following 8h treatment, BV-2 cell 
supernatants were processed using the RayBiotech cytokine antibody array III (Figure 6).  
This experiment was done one time for proof of principle.  Of the sixty-one proteins that 
can be detected using the system, twelve were selected for further analysis due to their 
change in expression between treatment groups: granulocyte colony-stimulating factor  
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Pos Pos Neg Neg Blank Axl BCL CD30L CD30L CD40 CRG-2 CTACK CXCL16 Eotaxin 
Pos Pos Neg Neg Blank Axl BCL CD30L CD30L CD40 CRG-2 CTACK CXCL16 Eotaxin 
Eotaxin 2 Fas-ligand Fractalkine GCSF GM-CSF INF-γ IGFBP-3 IGFBP-5 IGFBP-6 IL-1α IL-1β IL-2 IL-3 IL-3Rb 
Eotaxin 2 Fas-ligand Fractalkine GCSF GM-CSF INF-γ IGFBP-3 IGFBP-5 IGFBP-6 IL-1α IL-1β IL-2 IL-3 IL-3Rb 
IL-4 IL-5 IL-6 IL-9 IL-10 IL-12 IL-12p70 IL-13 IL-17 KC Leptin R Leptin LIX L-Selectin 
IL-4 IL-5 IL-6 IL-9 IL-10 IL-12 IL-12p70 IL-13 IL-17 KC Leptin R Leptin LIX L-Selectin 
Lymphot. MCP-1 MCP-5 M-CSF MIG MIP-1α MIP-1γ MIP 2 MIP 3β MIP 3α Pf 4 p-Selectin RANTES SCF 
Lymphot. MCP-1 MCP-5 M-CSF MIG MIP-1α MIP-1γ MIP 2 MIP 3β MIP 3α Pf 4 p-Selectin RANTES SCF 
SDF-1α TARC TCA-3 TECK TIMP-1 TNF- α sTNFRI sTNFRI TPO VCAM1 VERGF Blank Blank Pos 
SDF-1α TARC TCA-3 TECK TIMP-1 TNF- α sTNFRI sTNFRI TPO VCAM1 VERGF Blank Blank Pos 
 
Figure 6.  Effects the Cannabinoids THC and CP55940 on BV-2 Mouse Microglia-like 
Cell Extracellular Levels of Cytokines.  Supernatants from BV-2 cells treated (8h) with 
0.01% ethanol and sodium citrate (A), 50nM Tat + 0.01% ethanol (B), 50nM Tat +  10-6 M 
THC (C), and 50nM Tat + 10-6 M CP55940 (D) were subjected to RayBio Mouse Cytokine 
Array III.  Red boxes indicate positive controls, while blue boxes indicate negative 
controls.  Highlighted squares on the chart indicate cytokines and chemokines that were 
selected for further analysis. 
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(GCSF), insulin-like growth factor binding protein 3 (IGFBP-3), Interleukin 1 alpha (IL-
1α), LPS-induced CXC chemokine (LIX/CXCL5), monocyte chemotactic protein 1 (MCP-
1), monocyte chemotactic protein 5 (MCP-5), macrophage inflammatory protein 1 alpha 
(MIP-1α), macrophage inflammatory protein 1 gamma (MIP-1γ), macrophage 
inflammatory protein 2 (MIP-2), platelet factor 4 (PF-4), CCL5/RANTES, and soluble 
tumor necrosis factor receptor 1 (sTNFRI).  These proteins were selected as they exhibited 
differential levels between treatment groups, as measured by intensity/mm2 (Table 1). A 
graphical representation of these data is illustrated in Figure 7.  Tat treatment resulted in 
an increase in level of select proteins.   These data were  also graphed according to fold 
change compared to treatment with vehicle (Figure 8).  As indicated by fold change, select 
cytokines, such as GCSF and LIX had no increase in expression when treated with Tat.  
They did, however, have decreased expression below baseline when treated with 
cannabinoids.  Other chemokines, such as MIP-2, PF-4, MIPα, and RANTES showed an 
increase in level when treated with Tat.  This increase was ablated when cells were treated 
with the cannabinoids THC or CP55940.  In all cases,  treatment with Tat and the 
cannabinoid CP55940 resulted in a decrease in expression below baseline levels of 
expression of cells subjected to no treatment. 
 
Cytokine and Chemokine mRNA Profile by RT-PCR 
In order to gain insight as to the site-of-action at which THC and CP55940 acted to 
diminish levels of established cytokine, RT-PCR was performed using a PCR array 
provided by SABiosciences (PAMM-011Z). Briefly, BV-2 cell whole homogenates were  
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    Treatment       
Cytokine Vehicle         Tat      THC      CP Classification 
GCSF 107.1969 107.7232 96.06535 70.95646 Growth Factor 
IGFBP-3 45.71497 58.35166 36.46535 37.94978 Binding Protein 
IL-1α 106.9424 118.2773 77.18162 74.40868 Cytokine 
LIX 69.90219 70.96045 52.84831 31.44696 CXC Chemokine 
MCP1 408.2178 456.0289 334.7959 335.9918 CC Chemokine 
MCP-5 169.3697 202.2650 201.5582 128.8688 CC Chemokine 
MIP-1α 446.0233 564.6809 430.8201 342.1602 CC Chemokine 
MIP-1γ 619.2085 674.2853 570.2347 565.0322 CC Chemokine 
MIP-2 366.3371 484.0294 376.3764 328.9866 CXC Chemokine 
PF-4 122.3430 193.9887 143.0114 104.9401 CXC Chemokine 
RANTES 179.2407 264.3933 217.9427 163.9925 CC Chemokine 
sTNF RI 436.9920 484.4102 464.0807 383.1344 Receptor 
 
 
Table 1. Select Proteins Processed using the RayBiotech Cytokine Antibody Array 
III.  Shown in this table are the differential levels of select proteins as measured by 
intensity/mm2 when exposed to vehicle (sodium citrate +0.01% ethanol), Tat (50nM) + 
vehicle, Tat (50nM) + THC (10-6M), and Tat + CP55940 (10-6M). 
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Figure 7. Relative Levels of Select Cytokines and Chemokines Present in Culture 
Supernatants of BV-2 Cells Treated with the HIV protein Tat in Concert with THC 
or CP55,940. Supernatants from BV-2 cells treated (8h) with 0.01% ethanol and sodium 
citrate, 50nM Tat + 0.01% ethanol, 50nM Tat +  10-6 M THC, or 50nM Tat + 10-6 M 
CP55940 were subjected to RayBio Mouse Cytokine Array III.  The graph represents spots 
identified in the arrays and analyzed by densitometry. 
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Figure 8. Relative Levels of Select Cytokines and Chemokines Present in Culture 
Supernatants of BV-2 Cells Treated with the HIV Protein Tat in Concert with THC 
or CP55,940. Supernatants from BV-2 cells treated for 8h with 0.01% ethanol and sodium 
citrate (A), 50nM Tat + 0.01% ethanol (B), 50nM Tat +  10-6 M THC (C), and 50nM Tat + 
10-6 M CP55940 (D) were subjected to RayBio Mouse Cytokine Array III.  Each protein  
concentration is representative as a fold change compared to treatment with vehicle. 
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subjected to total RNA isolation, RT-PCR, and  assessment  for inflammatory cytokine and 
chemokine mRNAs following 8h exposure to Tat ± cannabinoids or vehicle.  Eighty-four 
inflammatory genes (Figure 9) were selected for assessment.  Heat map comparisons were 
established between treatment groups (Figures 10-12).  Among the 84 genes, 11 were 
selected for further analysis: Ccl11, Ccl5, Ccl8, Ccr2, Ccr3, Ccr5, Cxcl1, Cxcr5, Il17f, Il5, 
and Tnfsf11.  As shown in Figure 13, among these 11 genes, there was an increase in 
levels following exposure to the HIV inflammatory protein Tat.  This increased level of 
expression was partially or fully ablated by co-exposure (8h) of cells  to 10-6M THC or 
CP55940. 
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Position  Symbol  Description  Gene Name 
A01  Aimp1  Aminoacyl tRNA 
synthetase complex-
interacting 
multifunctional protein 1  
9830137A06Rik, AIMP1, p43, 
EMAPII, Emap2, Scye1, p43 
A02  Bmp2  Bone morphogenetic 
protein 2  
AI467020, Bmp2a 
A03  Ccl1  Chemokine (C-C motif) 
ligand 1  
BF534335, I-309, Scya1, Tca-3 
A04  Ccl11  Chemokine (C-C motif) 
ligand 11  
Scya11, eotaxin 
A05  Ccl12  Chemokine (C-C motif) 
ligand 12  
MCP-5, Scya12 
A06  Ccl17  Chemokine (C-C motif) 
ligand 17  
Abcd-2, Scya17, Scya17l, Tarc 
A07  Ccl19  Chemokine (C-C motif) 
ligand 19  
CKb11, ELC, MIP3B, Scya19, 
exodus-3 
A08  Ccl2  Chemokine (C-C motif) 
ligand 2  
AI323594, HC11, JE, MCAF, 
MCP-1, MCP1, SMC-CF, Scya2, 
Sigje 
A09  Ccl20  Chemokine (C-C motif) 
ligand 20  
CKb4, LARC, MIP-3A, MIP-
3[a], MIP3A, ST38, Scya20, 
exodus-1 
A10  Ccl22  Chemokine (C-C motif) 
ligand 22  
ABCD-1, DCBCK, MDC, 
Scya22 
A11  Ccl24  Chemokine (C-C motif) 
ligand 24  
CKb-6, MPIF-2, Scya24 
A12  Ccl3  Chemokine (C-C motif) 
ligand 3  
AI323804, G0S19-1, LD78alpha, 
MIP-1alpha, MIP1-(a), MIP1-
alpha, Mip1a, Scya3 
B01  Ccl4  Chemokine (C-C motif) 
ligand 4  
AT744.1, Act-2, MIP-1B, Mip1b, 
Scya4 
B02  Ccl5  Chemokine (C-C motif) 
ligand 5  
MuRantes, RANTES, SISd, 
Scya5, TCP228 
B03  Ccl6  Chemokine (C-C motif) 
ligand 6  
MRP-1, Scya6, c10 
B04  Ccl7  Chemokine (C-C motif) 
ligand 7  
MCP-3, Scya7, fic, marc, mcp3 
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B05  Ccl8  Chemokine (C-C motif) 
ligand 8  
1810063B20Rik, AB023418, 
HC14, MCP-2, Mcp2, Scya8 
B06  Ccl9  Chemokine (C-C motif) 
ligand 9  
CCF18, MRP-2, Scya10, Scya9 
B07  Ccr1  Chemokine (C-C motif) 
receptor 1  
Cmkbr1, Mip-1a-R 
B08  Ccr10  Chemokine (C-C motif) 
receptor 10  
Cmkbr9, Gpr2, MGC151420 
B09  Ccr2  Chemokine (C-C motif) 
receptor 2  
Cc-ckr-2, Ccr2a, Ccr2b, Ckr2, 
Ckr2a, Ckr2b, Cmkbr2, mJe-r 
B10  Ccr3  Chemokine (C-C motif) 
receptor 3  
CC-CKR3, CKR3, Cmkbr1l2, 
Cmkbr3, MGC124265, 
MGC124266 
B11  Ccr4  Chemokine (C-C motif) 
receptor 4  
CHEMR1, Cmkbr4, LESTR, 
MGC151418, Sdf1r 
B12  Ccr5  Chemokine (C-C motif) 
receptor 5  
AM4-7, CD195, Cmkbr5 
C01  Ccr6  Chemokine (C-C motif) 
receptor 6  
CC-CKR-6, CCR-6, Cmkbr6, 
KY411 
C02  Ccr8  Chemokine (C-C motif) 
receptor 8  
Cmkbr8, MGC123958, 
MGC123959, mCCR8 
C03  Cd40lg  CD40 ligand  CD154, CD40-L, Cd40l, HIGM1, 
IGM, IMD3, Ly-62, Ly62, T-
BAM, TRAP, Tnfsf5, gp39 
C04  Csf1  Colony stimulating factor 
1 (macrophage)  
C87615, Csfm, MCSF, op 
C05  Csf2  Colony stimulating factor 
2 (granulocyte-
macrophage)  
Csfgm, Gm-CSf, MGC151255, 
MGC151257, MGI-IGM 
C06  Csf3  Colony stimulating factor 
3 (granulocyte)  
Csfg, G-CSF, MGI-IG 
C07  Cx3cl1  Chemokine (C-X3-C 
motif) ligand 1  
AB030188, ABCD-3, AI848747, 
CX3C, Cxc3, D8Bwg0439e, 
Scyd1 
C08  Cxcl1  Chemokine (C-X-C 
motif) ligand 1  
Fsp, Gro1, KC, Mgsa, N51, 
Scyb1, gro 
C09  Cxcl10  Chemokine (C-X-C 
motif) ligand 10  
C7, CRG-2, INP10, IP-10, IP10, 
Ifi10, Scyb10, gIP-10, mob-1 
C10  Cxcl11  Chemokine (C-X-C 
motif) ligand 11  
Cxc11, H174, I-tac, Ip9, Itac, 
Scyb11, Scyb9b, b-R1, betaR1 
C11  Cxcl12  Chemokine (C-X-C 
motif) ligand 12  
AI174028, Pbsf, Scyb12, Sdf1, 
Sdf1a, Sdf1b, Tlsf, Tlsfa, Tlsfb, 
Tpar1 
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C12  Cxcl13  Chemokine (C-X-C 
motif) ligand 13  
4631412M08Rik, ANGIE2, 
Angie, BCA-1, BLC, BLR1L, 
Scyb13 
D01  Cxcl15  Chemokine (C-X-C 
motif) ligand 15  
Scyb15, lungkine, weche 
D02  Cxcl5  Chemokine (C-X-C 
motif) ligand 5  
AMCF-II, ENA-78, GCP-2, LIX, 
Scyb5, Scyb6 
D03  Cxcl9  Chemokine (C-X-C 
motif) ligand 9  
BB139920, CMK, Mig, MuMIG, 
Scyb9, crg-10 
D04  Cxcr2  Chemokine (C-X-C 
motif) receptor 2  
CD128, CDw128, Cmkar2, 
Gpcr16, IL-8Rh, IL-8rb, IL8RA, 
Il8rb, mIL-8RH 
D05  Cxcr3  Chemokine (C-X-C 
motif) receptor 3  
Cd183, Cmkar3 
D06  Cxcr5  Chemokine (C-X-C 
motif) receptor 5  
Blr1, CXC-R5, CXCR-5, Gpcr6, 
MDR15 
D07  Fasl  Fas ligand (TNF 
superfamily, member 6)  
APT1LG1, CD178, CD95-L, 
CD95L, Fas-L, Faslg, Tnfsf6, gld 
D08  Ifng  Interferon gamma  IFN-g, Ifg 
D09  Il10ra  Interleukin 10 receptor, 
alpha  
AW553859, CDw210, CDw210a, 
Il10r, mIL-10R 
D10  Il10rb  Interleukin 10 receptor, 
beta  
6620401D04Rik, AI528744, 
CRF2-4, Crfb4, D16H21S58, 
D21S58h, IL-10R2, Il10r2 
D11  Il11  Interleukin 11  IL-11 
D12  Il13  Interleukin 13  Il-13 
E01  Il15  Interleukin 15  AI503618 
E02  Il16  Interleukin 16  KIAA4048, mKIAA4048 
E03  Il17a  Interleukin 17A  Ctla-8, Ctla8, IL-17, IL-17A, Il17 
E04  Il17b  Interleukin 17B  1110006O16Rik, 
1700006N07Rik, Zcyto7 
E05  Il17f  Interleukin 17F  C87042, IL-17F 
E06  Il1a  Interleukin 1 alpha  Il-1a 
E07  Il1b  Interleukin 1 beta  IL-1beta, Il-1b 
E08  Il1r1  Interleukin 1 receptor, 
type I  
CD121a, CD121b, IL-iR, Il1r-1, 
MGC129154 
E09  Il1rn  Interleukin 1 receptor 
antagonist  
F630041P17Rik, IL-1ra 
E10  Il21  Interleukin 21  - 
E11  Il27  Interleukin 27  IL-27, IL-27p28, Il30, p28 
E12  Il2rb  Interleukin 2 receptor, CD122, IL-15Rbeta, IL15Rbeta, 
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beta chain  Il-2, 15Rbeta, Il-2Rbeta, 
MGC118674, p70 
F01  Il2rg  Interleukin 2 receptor, 
gamma chain  
CD132, [g]c, gamma(c), gc 
F02  Il3  Interleukin 3  BPA, Csfmu, HCGF, Il-3, 
MCGF, PSF 
F03  Il33  Interleukin 33  9230117N10Rik, Il-33, Il1f11, 
NF-HEV 
F04  Il4  Interleukin 4  Il-4 
F05  Il5  Interleukin 5  Il-5 
F06  Il5ra  Interleukin 5 receptor, 
alpha  
CD125, CDw125, Il5r 
F07  Il6ra  Interleukin 6 receptor, 
alpha  
CD126, IL-6R, Il6r, MGC30256 
F08  Il6st  Interleukin 6 signal 
transducer  
5133400A03Rik, AA389424, 
BB405851, CD130, 
D13Ertd699e, gp130 
F09  Il7  Interleukin 7  A630026I06Rik, Il-7, 
MGC129342, hlb368 
F10  Lta  Lymphotoxin A  LT, LT-[a], LT-alpha, LT[a], 
LTalpha, Ltx, MGC117668, 
TNF-beta, TNFSF1, Tnfb, 
Tnfsf1b, hlb382 
F11  Ltb  Lymphotoxin B  AI662801, LTbeta, Tnfc, Tnfsf3, 
p33 
F12  Mif  Macrophage migration 
inhibitory factor  
GIF, Glif, MGC107654 
G01  Nampt  Nicotinamide 
phosphoribosyltransferase  
1110035O14Rik, AI314458, 
AI480535, NAmPRTase, Pbef, 
Pbef1, Visfatin 
G02  Osm  Oncostatin M  OncoM 
G03  Pf4  Platelet factor 4  Cxcl4, Scyb4 
G04  Spp1  Secreted phosphoprotein 
1  
2AR, Apl-1, BNSP, BSPI, Bsp, 
ETA-1, Eta, OP, Opn, Opnl, Ric, 
Spp-1 
G05  Tnf  Tumor necrosis factor  DIF, MGC151434, TNF-alpha, 
TNFSF2, TNFalpha, Tnfa, 
Tnfsf1a 
G06  Tnfrsf11b  Tumor necrosis factor 
receptor superfamily, 
member 11b 
(osteoprotegerin)  
OCIF, Opg, TR1 
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G07  Tnfsf10  Tumor necrosis factor 
(ligand) superfamily, 
member 10  
A330042I21Rik, AI448571, 
APO-2L, Ly81, TL2, Trail 
G08  Tnfsf11  Tumor necrosis factor 
(ligand) superfamily, 
member 11  
Ly109l, ODF, OPG, OPGL, 
RANKL, Trance 
G09  Tnfsf13  Tumor necrosis factor 
(ligand) superfamily, 
member 13  
2310026N09Rik, April, 
MGC106105, Tall2, Trdl1 
G10  Tnfsf13b  Tumor necrosis factor 
(ligand) superfamily, 
member 13b  
BAFF, BLyS, D8Ertd387e, 
MGC124060, MGC124061, 
TALL-1, TALL1, THANK, 
TNFSF20, zTNF4 
G11  Tnfsf4  Tumor necrosis factor 
(ligand) superfamily, 
member 4  
Ath-1, Ath1, CD134L, OX-40L, 
Ox40l, TXGP1, Txgp1l, gp34 
G12  Vegfa  Vascular endothelial 
growth factor A  
Vegf, Vegf120, Vegf164, 
Vegf188, Vpf 
H01  Actb  Actin, beta  Actx, E430023M04Rik, beta-
actin 
H02  B2m  Beta-2 microglobulin  Ly-m11, beta2-m, beta2m 
H03  Gapdh  Glyceraldehyde-3-
phosphate dehydrogenase  
Gapd, MGC102544, 
MGC102546, MGC103190, 
MGC103191, MGC105239 
H04  Gusb  Glucuronidase, beta  AI747421, Gur, Gus, Gus-r, Gus-
s, Gus-t, Gus-u, Gut, asd, g 
H05  Hsp90ab1  Heat shock protein 90 
alpha (cytosolic), class B 
member 1  
90kDa, AL022974, C81438, 
Hsp84, Hsp84-1, Hsp90, Hspcb, 
MGC115780 
H06  MGDC  Mouse Genomic DNA 
Contamination  
MIGX1B 
H07  RTC  Reverse Transcription 
Control  
RTC 
H08  RTC  Reverse Transcription 
Control  
RTC 
H09  RTC  Reverse Transcription 
Control  
RTC 
H10  PPC  Positive PCR Control  PPC 
H11  PPC  Positive PCR Control  PPC 
H12  PPC  Positive PCR Control  PPC 
Table 2. Topographical representation of the PCR Array Plate.  The housekeeping 
genes were Ccl12, Csf1, Il6ra, and Gapdh.  
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Figure 9. Heat Map Illustrating the Magnitude of Levels of Cytokines/Chemokines 
Maintained in Vehicle Versus Tat. BV-2 cells were treated (8h) with 0.01% ethanol and 
sodium citrate (vehicle) or 50nM Tat + 0.01% ethanol (Tat).     
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Figure 10. Heat Map Illustrating the Comparison of the Magnitude of Levels of 
Cytokine/Chemokine  Maintained in Tat + vehicle versus Tat + THC.  BV-2 cells were 
treated (8h) with 50nM Tat + 0.01% ethanol (Tat)   and 50nM Tat + 10-6M THC (Tat + 
THC).  
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Figure 11. Heat Map Illustrating the Comparison of the Magnitude of Levels of 
Cytokine/Chemokine Maintained in Tat + Vehicle versus Tat + CP55940.  BV-2 cells 
were treated (8h) with 50nM Tat + 0.01% ethanol (Tat)   and 50nM Tat + 10-6M CP55940 
(Tat + CP).  
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Figure 12.   Gene Expression Profiles of Select Inflammatory Cytokines and 
Chemokines.  Following 8h treatment of BV-2 cells with 0.01% ethanol and sodium 
citrate (vehicle), 50nM Tat + 0.01% ethanol (Tat), 50nM Tat +  10-6 M THC (Tat + THC), 
or 50nM Tat + 10-6 M CP55940 (Tat + CP), cells were subjected to quantitative RT-PCR 
array (PAMM-011Z; SABiosciences).  Using web-based PCR array data analysis software 
provided by the manufacturer, fold-change compared to vehicle treatment was determined. 
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Discussion 
 
The advent and widespread use of HAART has substantially increased the lifespan 
of patients infected with HIV-1 (Ances, 2008).  With this increased life span is an 
increased chance to develop a myriad of HIV-associated neurocognitive disorders.  In 
addition, most retroviral therapies utilize a combination of therapies of nucleoside analog 
reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs).  HIV pro-
inflammatory protein Tat is not responsive to either of these actions and can therefore be 
responsible for inflammation in the brain.  It is therefore imperative to develop methods of 
treatment that can combat this inflammation caused by HIV protein Tat. 
 According to a review by Cabral (2001), cannabinoids can alter immune cells at 
high concentrations (10-5M or greater) by multiple modes of action, including physical 
disruption of membranes that could affect protein translational and post-translational 
events.  Also, at high concentrations, due to its lipophilic nature, THC’s interaction with 
cellular membranes could alter membrane fluidity, altering selective permeability (Wing, 
1985).  However, at low concentrations (less than 10-5M) cannabinoids may affect immune 
cell function through activation of cannabinoid receptors. Cannabinoids  may  be ideal 
therapeutic agents due to their specificity of action, low cytotoxicity, selectivity, and 
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ability to cross the blood-brain barrier in nanomolar levels.  While THC is only a partial 
agonist for the CB1R and CB2R, its use in experimental models yields insight regarding  
its drug abuse potential due to its deleterious psychoactive effects, and also gives valuable 
insight regarding specific molecular targets on immunocytes that have  translational 
application. 
 Our interest in finding  a therapeutic potential  started at the protein level and was 
approached from a pharmacological perspective.  Experiments were conducted to 
determine the effects of the cannabinoids THC and CP55940 on mouse microglial cells 
treated with Tat.  Simultaneous treatment of Tat and THC or Tat and CP55940 was 
employed because pre-treatment with cannabinoids is not biologically relevant.  The co-
exposure rationale is to try to imitate more closely what occurs in vivo, and if a subject is 
already infected with HIV, he/she will already have the occurrence of Tat expression.  In 
our experiments, BV-2 microglial-like cells were used. Although these cells are of mouse 
origin, they replicate most of the inflammatory responsiveness that has been attributed to 
human microglia in the context of HIV infection.  
Within the constraints of the paradigm selected, there were no major effects on the 
BV-2 intracellular proteome between treatment groups.  This was demonstrated using 2-D 
Gel Electrophoresis, which combines isoelectric focusing in the first dimension with with 
SDS-PAGE in the second dimension.  This approach has high resolving capacity for a 
complex protein mixture and allowed for separation and quantification of proteins in a pH 
range of 5-8.   There were no major changes in the proteome between treatment groups 
within the constraints of the experiment applied. However, it must be noted that analysis of 
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proteins occurred only within the range of pI 5 – 8 and it is possible that THC or CP55,940  
could alter the expression levels of proteins beyond this range. For example, highly basic 
proteins would focus extending beyond a PI of 8, and the present methodology did not 
allow for their resolution. For example, the protocol applied to the present studies did not 
address whether THC  or CP affected the expression of Tat-engendered proteins that could 
play a role in DNA binding or attaching to select DNA domains.  A similar argument 
applies for proteins that would focus in the acid range (i.e., below a pI of 5). Nevertheless, 
the results indicate that the level of the majority of proteins elicited by Tat that were within 
the PI range of 5-8 were not affected in a major fashion by THC of CP55,940. 
In contrast, there were overt effects on proteins that were secreted, as found by a 
microarray performed on supernatants of treated BV-2 cells.  Analysis of a subset of 
proteins tested indicate that a majority of these proteins were chemokines. In addition, a 
subset of tested cytokines and chemokines displayed a differential gene expression profiles 
between treatment groups, as verified by RT-PCR analysis. While these experiments need 
to be repeated for statistical validity, these observations suggest that THC and CP act 
primarily by inhibiting the expression of chemokines, and that they do so by altering their 
level of transcription. However, the mechanism by which this is effected remains to be 
defined. That is, whether a cannabinoid receptor is linked functionally to these events 
awaits further analysis.  
In summary, our findings are consistent with the hypothesis that select 
cannabinoids can ablate the pro-inflammatory response caused by HIV-1 pro-inflammatory 
protein Tat.  However, due to time constraints, it was not possible to address whether these 
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cannabinoid-mediated effects were linked functionally to a cannabinoid receptor.  A 
logical next step would be to perform Enzyme-linked immunosorbent assays (ELISAs) on 
select  chemokines and cytokines that showed significant downregulation with cannabinoid 
treatment.  Assessment of whether THC or CP cause a concentration-dependent inhibitory 
action suggestive of the involvement of a cannabinoid receptor, coupled with the 
appropriate use of receptor-selective cannabinoid receptor antagonists or anti-cannabinoid 
receptor mRNA siRNA technology, should provide insight as to whether a specified 
cannabinoid receptor subtype is involved. Ideally, if one were to avoid untoward 
psychoative properties that are associated with activation of the CB1R, a functional linkage 
would be found for the CB2R that is expressed on immune cells and is void of 
psychotropic action. Candidate chemokines for assessment include MIP-1α, MIP-2, PF-4, 
and RANTES as they showed the largest changes in secreted protein levels under 
experimental THC or CP exposure conditions.  
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